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Introduction
Creutzfeldt–Jakob disease (CJD) is a progressive neurode-
generative condition caused by the accumulation of toxic 
forms of prion protein in the brain. In 1985, reports emerged 
of patients who had developed CJD following treatment 
with cadaveric human growth hormone contaminated with 
prion protein, suggesting a transmissible aetiology. More 
recently detailed pathological analyses of brain tissue in 
these patients have unexpectedly revealed the co-existence 
of amyloid-beta protein (Aβ), the most common misfolded 
protein seen in the ageing brain, which is also implicated in 
the aetiology of Alzheimer’s disease and cerebral amyloid 
angiopathy.
Both prion protein and Aβ protein share similar properties 
including the ability to survive normal sterilisation proce-
dures. They are both able to grow and spread via nucleation-
dependent polymerisation processes, in which oligomeric 
seeds can promote the formation of an ordered nucleus that 
can form larger fibrils. The long incubation periods of these 
proteins can result in clinical and pathological evidence of 
disease becoming apparent decades after inoculation.
In this month’s journal club, we review three recent stud-
ies that explore the potential transmissibility of Aβ pathol-
ogy and which may have far-reaching implications. Two 
papers examine the pathological phenotype of protein accu-
mulation in patients who died from iatrogenic CJD following 
growth hormone supplementation. Both suggest that the high 
proportion of Aβ pathology seen in this group may indicate 
that the Aβ protein is transmissible via contaminated human 
growth hormone. The authors in these papers also suggest 
that contamination may occur via other sources such as 
human dura mater grafting and neurosurgical instrumenta-
tion. The third and most recent paper attempts to shed light 
on the aetiology of young-onset cerebral amyloid angiopathy 
in patients who had undergone childhood neurosurgery.
Evidence for human transmission 
of amyloid‑beta pathology and cerebral 
amyloid angiopathy
In this study, autopsy cases of eight patients who had died 
from iatrogenic CJD having received human growth hor-
mone were reviewed. Co-existence of significant Aβ pathol-
ogy in four of the eight cases (aged between 36 and 51) 
was identified. Three of the remaining patients also showed 
evidence of localised Aβ pathology. There was evidence 
of leptomeningeal amyloid angiopathy in 3 of the patients 
and focal amyloid angiopathy in one patient. The authors 
controlled for other genetic predispositions for alternative 
neurodegenerative conditions including Alzheimer’s disease, 
amyotrophic lateral sclerosis, fronto-temporal dementia and 
Parkinson’s disease. Screening was performed for variations 
in ApoE and 16 other alleles conferring a risk for early onset 
neurodegenerative conditions. When compared to a cohort 
of other CJD patients (85 sporadic CJD, 2 variant CJD and 
29 inherited prion disease) there was little or no evidence of 
Aβ in similar age groups using four different quantification 
methods. The group with similar levels of Aβ pathology 
was sporadic CJD patients who were of a much greater age 
(> 52).
As a result of these observations, the authors propose 
that a potential source of Aβ seeding could have been trans-
mission via human growth hormone. The authors went on 
to analyse the pituitary glands of 55 patients, 49 of whom 
had evidence of cerebral Aβ pathology. They found that in 
7 of 49 patients with parenchymal Aβ pathology, that there 
was also evidence of Aβ in the pituitary glands. The authors 
conclude that in patients with cerebral Aβ pathology, the 
existence of Aβ in their pituitary glands could have been a 
source of transmission into the human growth hormone pool.
Comment. This study suggests that this Aβ pathology in 
iatrogenic CJD patients is novel in comparison to pathology 
 * Neil P. Robertson 
 robertsonnp@cardiff.ac.uk
1 Department of Neurology, Institute of Psychological 
Medicine and Clinical Neurosciences, Cardiff University, 
Cardiff CF14 4XW, UK
1727Journal of Neurology (2018) 265:1726–1729 
1 3
found in older patients with amyloid angiopathy. How-
ever, it remains unclear whether it is the prion protein that 
‘seeds’ the Aβ protein. Other studies with larger cohorts 
have found significant Aβ pathology in the brains of spo-
radic CJD patients, raising the possibility that prion protein 
induces endogenous Aβ production. Against this theory is 
the authors’ observations that the prion protein and Aβ were 
not co-localised in their specimen samples. Despite the pres-
ence of Aβ, none of the patients exhibited clinical features of 
cerebral amyloid angiopathy or Alzheimer’s disease before 
death. Furthermore, no patients exhibited histological evi-
dence of other proteins implicated in the latter stages of Alz-
heimer’s disease pathology, such as tau protein.
The study is exploratory in nature and uses small num-
bers of cases which were analysed retrospectively from one 
centre. It is, therefore, difficult to draw definite conclusions 
about causality. Larger scale studies are needed to replicate 
these results, and experiments designed to explore whether 
or not Aβ protein is ‘seeded’ by prion protein.
Jaunmuktane Z et  al (2018) Acta Neuropathol 
135(5):671–679.
Amyloid‑beta accumulation in the CNS 
in human growth hormone recipients 
in the UK
This study investigated a large cohort of human growth hor-
mone recipient cases together with novel controls exploring 
the presence of prion protein and Aβ pathology. The authors 
analysed the brains of 35 patients who died from iatrogenic 
CJD following growth hormone supplementation, as well as 
five who developed CJD following human dura mater trans-
plantation. They also utilised a group of 12 age-matched 
controls who had received human growth hormone, but who 
did not go on to develop CJD. The authors sought to charac-
terise the spread and distribution of prion protein according 
to genotypic influences, whilst again controlling for genetic 
predispositions for neurodegenerative diseases.
The authors report that polymorphisms of endogenous 
prion protein at codon 129 did seem to determine the distri-
bution of prion protein, similar to that in sporadic CJD, and 
also influence disease duration, with MV heterozygosity of 
codon 129 conveying the longest disease duration. Further 
analysis revealed evidence of prion protein in non-CNS tis-
sues, including nerves, dorsal root ganglia and trigeminal 
ganglia in small numbers of non-CNS samples.
Aβ pathology was detected in 18 out of the 33 growth 
hormone patients who had developed iatrogenic CJD. This 
was seen as parenchymal deposits or cerebral amyloid 
angiopathy (6 amyloid angiopathy, 4 parenchymal Aβ, 8 
both). Importantly, 5/12 human growth hormone controls 
(who did not develop iatrogenic CJD) also showed CNS 
Aβ accumulation (three parenchymal, one limited amyloid 
angiopathy, one diffuse amyloid angiopathy and cortical 
plaques). In neither group was the accumulation of Aβ suf-
ficient to make a pathological diagnosis of Alzheimer’s dis-
ease, nor was there clinical evidence of Alzheimer’s disease. 
Similar proportions of patients exhibiting Aβ pathology 
were not seen in 33 variant CJD patients nor the 15 (older) 
sporadic CJD patients. There was also little evidence of co-
localisation of prion protein and Aβ, further suggesting that 
prion protein could not be the lone precipitant in ‘seeding’ 
endogenous Aβ pathology. None of the human dura mater 
transplantation patients had evidence of Aβ pathology.
The presence of Aβ in patients with iatrogenic CJD did 
not correlate with their length of growth hormone treat-
ment nor their age at death, however, in human growth hor-
mone recipients who did not develop iatrogenic CJD, being 
positive for Aβ was moderately correlated with earlier and 
longer duration of treatment with human growth hormone. 
There was no significant correlation between APOE-e3/4 
or APOE-4 positivity and Aβ pathology and there was no 
significant influence of genetic predispositions for neurode-
generative diseases.
The authors conclude that Aβ pathology could be trans-
mitted via growth hormone supplementation independently 
of prion protein.
Comment. This study uses large numbers of patients, and 
advanced techniques in detection and stratification of both 
prion protein and Aβ. Genotypic analysis of the prion pro-
tein at codon 129 gives us some clues as to the genotypic 
influences which determine where the contaminated prion 
protein is located, and the likely disease severity measured 
according to disease duration before death. Given the small 
numbers of non-CNS samples analysed it is difficult to 
suggest peripheral rather than CNS transmission of prion 
protein.
Importantly, the similar levels of Aβ in the human growth 
hormone recipient group who did not develop iatrogenic 
CJD points to independent transmission of both proteins. 
Care needs to be taken in analysing this group because of 
small numbers (12) and by the presence of possible other co-
morbidities causing their significantly shortened life span.
Aβ pathology accumulation seems to be a dynamic pro-
cess, and the use of purely autopsy date does limit our inter-
pretations as to the growth and spread of Aβ pathology with 
time. Significantly, in this study, none of the patients exhib-
ited the clinical features of a neurodegenerative condition 
despite the presence of Aβ pathology. This may be in part 
due to the fact that patients who developed Aβ following 
growth hormone supplementation died at a young age.
Ritchie DL et  al  (2017) Acta Neuropathol 
134(2):221–240.
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Evidence of amyloid‑β cerebral 
amyloid angiopathy transmission 
through neurosurgery
This study comprises a retrospective analysis of a case series 
of young-onset cerebral amyloid angiopathy presenting in 
to a UK centre between 2002 and 2016. The authors identi-
fied five biopsy-proven cases and one-autopsy proven case 
in a pathology archive, and six cases from the published 
literature. None of these patients had evidence of CJD. The 
authors interrogated case records for evidence of early child-
hood neurosurgical procedures as a predisposing factor for 
cerebral amyloid angiopathy.
In 3/5 of the biopsy cases, detailed history taking con-
firmed childhood neurosurgical intervention (secondary to 
trauma, congenital malformations and tumour resection). All 
of these patients had presented to hospital decades later fol-
lowing an intracerebral haemorrhage, and had their biopsy 
taken at that point. In the single autopsy case from a patient 
who had died following intracerebral haemorrhage, there 
was also a history of early neurosurgical intervention (sec-
ondary to syringomyelia). In all of these pathological cases, 
there was histological evidence of diffuse Aβ pathology. 
When samples of 50 age-matched controls (who had under-
gone cerebral biopsy for other reasons) were analysed, no 
evidence of Aβ pathology was identified.
A supplementary literature review of early onset cerebral 
amyloid angiopathy patients identified six cases. In all cases 
there was evidence of previous penetrating brain injury. In 
two cases there was also a record of childhood neurosurgi-
cal intervention, whilst a further two had radiological evi-
dence of early-life neurosurgical intervention. Since there 
was no history of penetrating traumatic brain injury in their 
own pathological cohort, the authors conclude that the most 
likely correlate of young-onset cerebral amyloid angiopa-
thy appears to be early-life neurosurgical intervention. Fur-
thermore, the authors suggest that Aβ proteopathic seeds 
may have been transmitted by surgical instruments carrying 
traces of misfolded Aβ.
Comment. This study is the first to draw a direct link 
between a possible route of Aβ transmission and a clini-
cal manifestation of Aβ pathology. The study used focussed 
clinical history to determine pre-existing factors that may 
have predisposed to the development of cerebral amyloid 
angiopathy.
The study did draw from biopsy samples taken in vivo, 
thus not all data were retrospective. However, without pro-
spective modelling it is difficult to adequately characterise the 
clinical phenotypes of these patients. Indeed there is limited 
clinical information for a number of these patients, including 
the details of relevant neurosurgical procedures. Furthermore, 
the evidence of early penetrating traumatic brain injury in the 
literature review group cannot be discounted as a potential 
cause of Aβ accumulation.
Although a high incidence of Aβ was seen in this cohort 
of patients, care needs to be taken in extrapolating from such 
a small sample. Cerebral amyloid angiopathy patients above 
55 were excluded in the biopsy cohort, and those over 57 
were excluded in the autopsy group. Perhaps including older 
patients in their analysis would increase numbers and provide 
further information about predisposing factors for develop-
ment of cerebral amyloid angiopathy, although the existence 
of ‘sporadic’ Aβ protein in this age group would be a con-
founding problem. Further studies looking prospectively at the 
development of Aβ pathology in well-characterised controlled 
groups of patients undergoing neurosurgery may be of benefit.
Jaunmuktane Z et  al (2018) Acta Neuropathol 
135(5):671–679.
Conclusions. These studies highlight a rare but important 
possible sequelae of growth hormone supplementation, as well 
as other possible sources of protein seeding, including surgi-
cal instrumentation. The studies have all used up to date- and 
highly advanced techniques in characterising the presence 
of Aβ as well as prion protein, and in controlling for other 
co-morbidities. Collectively, these studies present important 
preliminary evidence for the transmissibility of Aβ protein in 
humans. The authors’ hypotheses are also supported by evi-
dence of iatrogenic transmissibility of Aβ in murine models 
by both intracerebral and peripheral routes.
All patients who developed iatrogenic CJD had growth hor-
mone via the Wilhelmi preparation, and there is a suggestion 
that techniques used in this preparation specifically allow prion 
protein as well as Aβ to survive within the growth hormone 
batch. There is less evidence for the presence of Aβ protein 
being present on neurosurgical instruments, and this could be 
an important future focus for research. In addition, a more 
detailed understanding of the properties of Aβ protein that 
allow it to become transmissible and able to survive stand-
ard sterilisation techniques may help prevent future cases of 
transmission.
Future studies looking at the epidemiological clinical corre-
lates of Aβ transmission would be of value. Studies exploring 
the prevalence of neurodegenerative diseases in a large popu-
lation of those who have undergone human growth hormone 
supplementation may be relevant. Large-scale studies follow-
ing up patients who have undergone brain instrumentation via 
neurosurgery may also be interesting. All of these studies are 
limited by small numbers, lack of robust clinical correlations, 
and difficulty extrapolating across different centres. Given the 
shift in modern neurosurgical techniques, sterilisation proce-
dures, and the discontinuation of human growth hormone, it 
may be that the rates of transmissibility are currently much 
lower or absent.
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